LUNG (Pulmonx) ROCE % : -34.21% (As of Sep. 2024)

View and export this data going back to 2020. Start your Free Trial

What is Pulmonx ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Pulmonx's annualized ROCE % for the quarter that ended in Sep. 2024 was -34.21%.

Pulmonx ROCE % Historical Data

The historical data trend for Pulmonx's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Pulmonx ROCE % Chart

Pulmonx Annual Data

Trend

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

ROCE %

Get a 7-Day Free Trial

-77.83

-19.85

-20.26

-29.28

-34.59

Pulmonx Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
ROCE %	Get a 7-Day Free Trial															-33.00	-31.92	-34.05	-38.32	-34.21

Pulmonx ROCE % Calculation

Pulmonx's annualized ROCE % for the fiscal year that ended in Dec. 2023 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	-57.04	/	( ( (193.676 - 18.492)	+	(177.781 - 23.157) )	/ 2 )
	=	-57.04	/	( (175.184	+	154.624)	/ 2 )
	=	-57.04	/	164.904
	=	-34.59 %

Pulmonx's ROCE % of for the quarter that ended in Sep. 2024 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Sep. 2024 )		(Q: Jun. 2024 )		(Q: Sep. 2024 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Sep. 2024 )		(Q: Jun. 2024 )		(Q: Sep. 2024 )
	=	-52.244	/	( ( (172.627 - 16.301)	+	(167.401 - 18.3) )	/ 2 )
	=	-52.244	/	( ( 156.326	+	149.101 )	/ 2 )
	=	-52.244	/	152.7135
	=	-34.21 %

(1) Note: The EBIT data used here is four times the quarterly (Sep. 2024) EBIT data.

Pulmonx (NAS:LUNG) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Pulmonx ROCE % Related Terms

Thank you for viewing the detailed overview of Pulmonx's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

Pulmonx Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Pulmonx Corp (NAS:LUNG) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

N/A

Address

700 Chesapeake Drive, Redwood, CA, USA, 94063

Website

https://www.pulmonx.com

Pulmonx Corp is a commercial-stage medical technology company. It provides a minimally invasive treatment for patients with severe emphysema, a form of chronic obstructive pulmonary disease (COPD). The company's solutions are comprised of the Zephyr Endobronchial Valve, the Chartis Pulmonary Assessment System and the StratX Lung Analysis Platform. It generates revenue through the sale of products to distributors and hospitals in the United States which a key revenue generating market, Europe, Middle-East and Africa, Asia Pacific and other regions.

Executives

David Aaron Lehman	officer: General Counsel	C/O INTERSECT ENT, INC., 1555 ADAMS DRIVE, MENLO PARK CA 94025
Geoffrey Beran Rose	officer: Chief Commercial Officer	5124 ROCKWOOD PARKWAY NW, WASHINGTON DC 20016
French Glendon E. Iii	director, officer: President and CEO	700 CHESAPEAKE DRIVE, REDWOOD CITY CA 94063
John Mckune	officer: Interim CFO	46668 CRAWFORD CT., FREMONT CA 94539
Derrick Sung	officer: Chief Financial Officer	C/O IRHYTHM TECHNOLOGIES, INC., 650 TOWNSEND STREET, SUITE 380, SAN FRANCISCO CA 94103
Alissa Hsu Lynch	director	700 CHESAPEAKE DRIVE, REDWOOD CITY CA 94063
Richard M Ferrari	director	2118 WALSH AVENUE, SUITE 210, SANTA CLARA CA 95050
Tiffany Sullivan	director	700 CHESAPEAKE DRIVE, REDWOOD CITY CA 94063
Boston Scientific Corp	10 percent owner	300 BOSTON SCIENTIFIC WAY, MARLBOROUGH MA 01752-1234
Daniel P Florin	director	56 E. BELL DRIVE, WARSAW IN 46581
Mead Dana G Jr.	director	2750 SAND HILL ROAD, MENLO PARK CA 94025
Thomas William Burns	director	C/O GLAUKOS CORPORATION,, 26051 MERIT CIRCLE, SUITE 103, LAGUNA HILLS CA 92653
Georgia Melenikiotou	director	C/O INSPIRE MEDICAL SYSTEMS, INC., 5500 WAYZATA BOULEVARD, SUITE 1600, GOLDEN VALLEY MN 55416
Staffan Lindstrand	director	C/O ODLANDER, FREDRIKSON & CO. AB, STRANDVAGEN 5B, STOCKHOLM V7 SE-114 51